InvestorsHub Logo
Followers 32
Posts 1683
Boards Moderated 0
Alias Born 01/11/2014

Re: Oren1976 post# 1509

Thursday, 10/19/2017 1:03:21 AM

Thursday, October 19, 2017 1:03:21 AM

Post# of 2099
Oren, not sure what is your point. Avastin is an affective anti-cancer therapy and its MOA is based on reducing angiogenesis, including tumor's angiogenesis. It has significantly improved OS in many types of cancer (not brain cancer though for which it has demonstrated just a PFS improvement) and it is approved for many cancer types, fetching peak sales in excess of $7B per annum. VB 111 seems to be more tumor specific and also causing an additional immune reaction. The combination of the two has proved more effective in prolonging mOS in ph2 vs Avastin monotherapy in rGBM, hence the decision to have the combination for the whole ph3 duration Maybe the two drugs are not synergistic, but it seems that two are better than one in this case.
What is your point? What are you trying to prove or disprove?
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent VBLT News